Linvoseltamab + Daratumumab
Phase 3Recruiting 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
High Risk Smoldering Multiple Myeloma (HR-SMM)
Conditions
High Risk Smoldering Multiple Myeloma (HR-SMM)
Trial Timeline
Mar 25, 2026 → Jul 22, 2033
NCT ID
NCT07393282About Linvoseltamab + Daratumumab
Linvoseltamab + Daratumumab is a phase 3 stage product being developed by Regeneron Pharmaceuticals for High Risk Smoldering Multiple Myeloma (HR-SMM). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07393282. Target conditions include High Risk Smoldering Multiple Myeloma (HR-SMM).
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07393282 | Phase 3 | Recruiting |
Competing Products
20 competing products in High Risk Smoldering Multiple Myeloma (HR-SMM)